AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aptevo Therapeutics Inc. Director's Dealing 2018

Mar 6, 2018

35422_dirs_2018-03-05_118ab2fa-1fae-4ac9-be04-41dbfed210c6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aptevo Therapeutics Inc. (APVO)
CIK: 0001671584
Period of Report: 2018-03-01

Reporting Person: Gross Jane A (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-01	Common Stock	M	9140	—	Acquired	95709	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-01	Restricted Stock Unit	$	M	9140	Disposed		Common Stock (9140)	Direct

Footnotes

F1: Each RSU converts into the Issuer's common stock on a one-for-one basis.

F2: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest as follows: 9,140 on March 1, 2017, 9,140 on March 1, 2018 and 9,138 on March 1, 2019.